- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04384367
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
A Multicenter, Double-blind, Double-dummy, Randomized, Single-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine.
⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, randomized, double-blind, double-dummy and placebo-controlled study in individuals with disabling migraine. The participants will be randomized to receive Rizatriptan + Naproxen (10/550mg), Rizatriptan (10mg), Naproxen (550mg) or placebo.
⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Edilene Macedo, Analyst
- Phone Number: 5511 5090-8422
- Email: edilene.macedo@eurofarma.com
Study Contact Backup
- Name: Natalia A Gianni, Analyst
- Phone Number: 41449500
- Email: natalia.gianni@eurofarma.com
Study Locations
-
-
-
São Paulo, Brazil, 06696-000
- Recruiting
- Eurofarma Laboratorios S.A
-
Contact:
- Edilene Macedo
- Phone Number: 8422 55 11 50908600
- Email: edilene.macedo@eurofarma.com
-
-
SP
-
São Paulo, SP, Brazil
- Recruiting
- CEPIC
-
Contact:
- Vanessa Pádua
- Email: vanessa.padua@cepic.com.br
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients of both sexes;
- Aged between 18 and 65 years old;
- Capable and willing to give free and informed informed consent in writing;
- Migraine patients with or without aura, according to the International Headache Society (IHS).
Exclusion Criteria:
- Chronic migraine;
- Headache other than migraine (that is, tension-type headache, sinusitis, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
oral - single dose
Other Names:
|
Experimental: Rizatriptan 10mg+ Naproxen 550mg
|
oral - single dose
Other Names:
|
Active Comparator: Maxalt 10mg
Rizatriptan10mg
|
oral - single dose
Other Names:
|
Active Comparator: Flanax 550mg
Naproxen 550mg
|
oral - single dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-hour pain-free
Time Frame: 11 weeks
|
2-hour pain-free response (Proportion of participants reporting pain freedom at two hours post-dose)
|
11 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Most bothersome migraine-associated symptom
Time Frame: 11 weeks
|
Migraine-associated symptoms: nausea, vomiting, photophobia or phonophobia and phonophobia (frequency)
|
11 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Serotonin Agents
- Serotonin Receptor Agonists
- Gout Suppressants
- Naproxen
- Rizatriptan
Other Study ID Numbers
- EF167
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Rizatriptan 10 mg + Naproxen 550mg
-
Organon and CoCompletedMigraine Disorders
-
Organon and CoCompleted
-
Dow University of Health SciencesRecruitingAcute Apical AbscessPakistan
-
Merck Sharp & Dohme LLCCompleted
-
Johnson & Johnson Consumer Inc., McNeil Consumer...Completed
-
The Cleveland ClinicGlaxoSmithKline; Currax PharmaceuticalsCompletedWorkplace Migraine TreatmentUnited States
-
Galeno Desenvolvimento de Pesquisas ClínicasBiolab Sanus FarmaceuticaCompleted
-
Merck Sharp & Dohme LLCCompleted
-
PfizerCompleted
-
PfizerCompleted